Publications by authors named "Nicole L Watts"

2 Publications

  • Page 1 of 1

Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.

Biol Blood Marrow Transplant 2019 02 13;25(2):233-238. Epub 2018 Sep 13.

Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama. Electronic address:

Filgrastim (FIL) is the most common growth factor combined with plerixafor for autologous hematopoietic progenitor cell mobilization, but requires daily, multi-injection administration. We adopted a standardized mobilization regimen with pegfilgrastim (PEG) and upfront plerixafor, allowing for a single injection given the long half-life and slow elimination of PEG. Between 2015 and 2017, a total of 235 patients with lymphoma or plasma cell dyscrasias underwent mobilization with PEG 6 mg on day 1 and upfront plerixafor 24 mg on day 3, followed by apheresis on day 4 regardless of peripheral blood CD34 cells. The median CD34 cells/mm in peripheral blood on first day of collection was 48 and median collection yield was 7.27 × 10 CD34 cells/kg (range, 0.32 to 39.6 × 10 CD34 cells/kg) after a mean of 1.6 apheresis collections. Overall, 83% of patients achieved the mobilization target, and 95% reached the minimum necessary CD34 cell yield to proceed with transplantation (2 × 10 CD34 cells/kg). Because FIL is weight-based and dosed daily, the cost comparison with PEG is influenced by patient weight and number of apheresis sessions required. A cost simulation using actual patient data indicates that PEG is associated with lower cost than FIL for the majority of patients. Autologous hematopoietic progenitor cell mobilization with PEG and plerixafor is practical, effective, and not associated with increased cost compared with FIL mobilization.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2018.09.005DOI Listing
February 2019

Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors.

Clin Colorectal Cancer 2014 Jun 27;13(2):127-30. Epub 2013 Dec 27.

Division of Hematology/Oncology, Department of Medicine and the UVA Cancer Center, University of Virginia Health System, Charlottesville, VA.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clcc.2013.12.003DOI Listing
June 2014